The FDA approved a fixed-dose combination of carbachol and brimonidine tartrate for presbyopia, offering a noninvasive ...
Dealbreaker on MSN
Presbyopia eye drop from startup Tenpoint gets FDA approval, paving way for $235M financing
Tenpoint Therapeutics’ Yuvezzi brings a combination approach to presbyopia compared to single mechanisms of action offered by once-daily eye drops from Orasis Pharmaceuticals, Lenz Therapeutics, and ...
A new treatment vertical in eye care, pharmacologic agents for refractive correction, is in the early stage of ...
Tenpoint Therapeutics’ Yuvezzi gets US FDA nod; the first and only combo eye drop approved to treat presbyopia: London Saturday, January 31, 2026, 14:00 Hrs [IST] Tenpoint Thera ...
The FDA has approved the first dual-agent eye drop to treat presbyopia, a condition that causes gradual loss of near vision in adults.
YUVEZZI (TM) (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% is a dual-agent eye drop approved by the U.S. Food & Drug Administration (FDA) for the treatment of presbyopia, a ...
MedPage Today on MSN
FDA OKs More Eye Drops That Can Replace Reading Glasses
Once-daily carbachol/brimonidine tartrate significantly improves aging-related vision loss ...
Credit: Alcon. Access initiatives including a First Fill Free trial program and an ongoing copay support will be available for eligible patients. The active ingredient in Tryptyr is acoltremon, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results